Mepolizumab
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Mepolizumab
- Mepolizumab: From Severe Eosinophilic Asthma to Thrombocytopenia Due to Immune Destruction
Mepolizumab: From Severe Eosinophilic Asthma to Thrombocytopenia Due to Immune Destruction
One-Sentence Summary
Mepolizumab is an anti-IL-5 monoclonal antibody originally approved for severe eosinophilic asthma and hypereosinophilic syndrome (HES), reducing eosinophil counts by blocking the IL-5 cytokine. The TxGNN model predicts it may be effective for Thrombocytopenia Due to Immune Destruction, with 0 clinical trials and 1 publication currently available to support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Severe eosinophilic asthma, hypereosinophilic syndrome (HES) |
| Predicted New Indication | Thrombocytopenia Due to Immune Destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, Mepolizumab is an anti-IL-5 monoclonal antibody whose efficacy in severe eosinophilic asthma and hypereosinophilic syndrome (HES) has been established. Mechanistically, it may be indirectly relevant to immune-mediated thrombocytopenia through the eosinophil-platelet axis.
The proposed link works as follows: excessive IL-5 signalling drives eosinophil tissue infiltration, causing release of major basic protein (MBP) and eosinophilic cationic protein (ECP). These granule mediators can activate complement and trigger immune-mediated platelet destruction. By suppressing eosinophil counts, Mepolizumab could indirectly relieve HES-associated immune thrombocytopenia. The single available case report documents a patient with steroid-resistant hypereosinophilic immune diathesis who showed simultaneous resolution of a mixed thrombotic microangiopathy following Mepolizumab treatment, providing anecdotal but not controlled support for this hypothesis.
It is important to emphasise that this mechanistic link is secondary and indirect — not an independent, direct therapeutic pathway. The prediction likely reflects the biological proximity between eosinophilic disorders and certain platelet destruction syndromes in the knowledge graph, rather than a stand-alone repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case Report | Blood Cells, Molecules & Diseases | A patient with steroid-resistant hypereosinophilic immune diathesis treated with Mepolizumab showed full resolution of symptoms; concomitant amelioration of mixed thrombotic microangiopathy was observed, suggesting that IL-5-driven eosinophilia may contribute to platelet-related immune injury and that its suppression could have secondary haematological benefit |
India Market Information
Mepolizumab currently has no registered products in India (0 authorisations on record). The drug is not marketed locally and would require full regulatory filing before any clinical use.
Additional Predicted Indications (TxGNN Top 5)
For reference, all five top-ranked predictions share a common theme of platelet disorders, suggesting that the model is capturing an eosinophil–platelet biology cluster rather than distinct individual targets.
| Rank | Disease | TxGNN Score | Evidence Level | Mechanistic Confidence | Decision |
|---|---|---|---|---|---|
| 1 | Thrombocytopenia due to immune destruction | 99.66% | L4 | Moderate (indirect via HES/MBP pathway) | Hold |
| 2 | Primary release disorder of platelets | 99.61% | L4 | Low (eosinophil–platelet aggregates, basic research only) | Hold |
| 3 | Pseudo-von Willebrand disease | 99.44% | L5 | Very low (GPIbα mutation, no IL-5 connection) | Hold |
| 4 | Autoimmune thrombocytopenic | 99.33% | L5 | Low (Th2/eosinophil involvement possible, not mainstream ITP pathway) | Hold |
| 5 | Glanzmann thrombasthenia | 99.29% | L5 | None (structural GPIIb/IIIa deficiency, unrelated to IL-5) | Hold |
⚠️ The clustering of platelet disorders in positions 1–5 is a known knowledge-graph topology effect. High TxGNN scores within a disease cluster do not independently validate each indication; biological plausibility must be assessed individually.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to a single anecdotal case report with an indirect mechanistic link; no clinical trials exist for this indication, detailed MOA and safety data are unavailable, and Mepolizumab is not currently registered in India.
To proceed, the following is needed:
- Obtain the full prescribing information (FDA/EMA label) to fill critical safety gaps: warnings, contraindications, and DDI profile
- Characterise the mechanism of action more precisely — particularly whether eosinophil suppression independently reduces immune platelet destruction versus being a co-phenomenon in HES
- Search for retrospective data or post-hoc analyses in HES cohorts for thrombocytopenia as a secondary endpoint
- Design a pilot prospective study in HES patients with concurrent immune thrombocytopenia before committing to a standalone repurposing programme
- Initiate India regulatory pathway assessment (new drug registration) since the drug has zero local approvals
- Commission a formal systematic review to determine whether the platelet-disorder clustering in TxGNN reflects a true biological signal or a graph topology artefact
Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.